CUTIA-B (02487) rose more than 3% during trading. At the time of writing, the stock was up 3.25%, trading at HK$4.76, with a turnover of HK$409,900.

The company announced the completion of its Chinese Phase III clinical trial for CU-20101, an injectable Type A botulinum toxin intended to improve moderate to severe glabellar lines. The trial was designed to evaluate the efficacy and safety of both single and repeated injections of CU-20101 for treating moderate to severe glabellar lines. The study used the reference product BOTOX® (onabotulinumtoxinA) as a control.

All participants completed the trial in November 2025, and the database was locked in January 2026, with positive topline results achieved.